Targeting TDP-43 meditated neurodegeneration for therapitic benefit in dementia
Status / Stage
ActiveDates
1 May 2021 -30 April 2024
Duration (calculated)
02 years 11 monthsFunder(s)
Alzheimer's Research UKFunding Amount
£174,904.00Funder/Grant study page
Alzheimer's Research UKContracted Centre
King's Collefe London, Institute of Psychiatry, Psychology & NeurosciencePrincipal Investigator
Dr Matthew WhitePI Contact
matthew.white@kcl.ac.ukPI ORCID
0000-0002-4147-4267WHO Catergories
Understanding risk factorsUnderstanding Underlying Disease
Disease Type
Alzheimer's Disease (AD)CPEC Review Info
| Reference ID | 230 |
|---|---|
| Researcher | Reside Team |
| Published | 12/06/2023 |
Data
| Status / Stage | Active |
|---|---|
| Start Date | 20210501 |
| End Date | 20240430 |
| Duration (calculated) | 02 years 11 months |
| Funder/Grant study page | Alzheimer's Research UK |
| Contracted Centre | King's Collefe London, Institute of Psychiatry, Psychology & Neuroscience |
| Funding Amount | £174,904.00 |
Aims
Dr Matthew White’s Alzheimer’s Research UK Fellowship will further our understanding of this process. He will use cutting edge stem cell techniques to grow nerve cells in the lab and investigate how they change when the regulation of TDP-43 is disrupted. His research will also be extended to using the lab-grown nerve cells to study how potential drugs could reverse some of those effects. This Fellowship will not only build our understanding of a vital process that occurs during FTD but may also identify approaches that could be used in the treatment of the disease.